Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced promising preclinical results for its tri-specific T-cell engager, MP0533, designed for treating Relapsed/Refractory Acute Myeloid Leukemia (AML) and high-risk Myelodysplastic Syndromes (MDS). The study demonstrated significant AML cell-specific cytotoxicity with reduced off-tumor effects, potentially enhancing safety. A Phase I clinical trial evaluating MP0533's safety and dosage is set to start soon. The drug's mechanism targets multiple tumor-associated antigens, aiming for improved therapeutic outcomes.
Molecular Partners AG (NASDAQ: MOLN) presented positive interim results from its Phase 1 trial of MP0317 for solid tumors at the SITC 2022 conference. This trial shows localized CD40 activation with no systemic toxicities, a significant issue with other CD40 agents. As of November 1, 2022, 19 patients have been enrolled, with initial data indicating safety and tolerability. The company aims to continue dose escalation, potentially leading to a Phase 2 trial. Molecular Partners emphasizes the innovative role of DARPin therapeutics in overcoming historical challenges in cancer treatment.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced an upcoming presentation at the American Society of Hematology (ASH) Annual Meeting in New Orleans, scheduled for December 9-13, 2022. The presentation will feature MP0533, a multispecific DARPin CD3 engager targeting CD33, CD123, and CD70 for treating AML and MDS, specifically designed to target leukemic stem cells. It will occur on December 12, 2022, at 5:45 PM. In addition, the company plans to host an investor event on December 10, featuring discussions with industry Key Opinion Leaders.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company, announced its upcoming presentations at several investor and scientific conferences. Initial data from the Phase 1 Trial of MP0317 for solid tumors will be showcased at the Society for Immunotherapy of Cancer (SITC) Meeting in Boston from November 10-12, 2022. Additional investor meetings are scheduled at the Credit Suisse Equity Forum on November 15 and at the Evercore ISI HealthCONx Conference on November 29, where company overviews will be presented.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced its interim management statement for Q3 2022, reporting significant progress in its oncology programs, including MP0317 and MP0533. The initial clinical data for MP0317 will be presented at SITC in November 2022, while MP0533 is on track for clinical development by year-end. Financial highlights include CHF 267 million in cash and an operating profit of CHF 132 million for the nine months ending September 30, 2022. The company expects to be funded into 2026, excluding R&D partnership revenues.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the departure of Chief Financial Officer, Andreas Emmenegger, at the end of 2022. Emmenegger, who has been with the company for 15 years, will aid in the transition while a replacement is sought. CEO Patrick Amstutz praised Emmenegger’s contributions, highlighting the successful IPOs on both the SIX Swiss Exchange and Nasdaq under his financial leadership. Molecular Partners focuses on DARPin therapeutics, with numerous partnerships and ongoing clinical developments across various therapeutic areas.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced key corporate highlights and financial results for H1 2022, reporting total revenues of CHF 184.5 million, attributed mainly to a CHF 150 million payment from Novartis for licensing ensovibep. The company holds a strong cash position of CHF 285.1 million expected to fund operations into 2026.
Ongoing clinical developments include MP0317 and MP0533, with initial data from MP0317 anticipated in H2 2022. Molecular Partners' strategic focus is on advancing novel DARPin therapeutics to address significant health challenges.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) will release its H1 2022 highlights and financial results on August 25, 2022, at 4:30 pm ET. Following this, an analyst and investor call is scheduled for August 26, 2022, at 8:00 am ET. The call will be webstreamed and available for 90 days post-event. Molecular Partners focuses on DARPin therapeutics, aiming to address challenges in diverse medical fields including ophthalmology, oncology, and infectious diseases.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced preclinical findings on ensovibep, a tri-specific DARPin therapeutic targeting SARS-CoV-2, published in Nature Biotechnology. Key results demonstrate ensovibep's ability to bind to all units of the viral spike protein, inhibiting ACE2 interaction. It shows efficacy against SARS-CoV-2 variants, including Omicron strains. These findings support ongoing clinical development for Emergency Use Authorization by the FDA. Molecular Partners plans to expand its antiviral DARPin portfolio for future health threats.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced its participation in several key conferences in June 2022, highlighting developments in their DARPin therapeutics aimed at treating various diseases. At the European Hematology Association Conference, they will present data on MP0533, a T-cell engager targeting tumors. Additionally, Novartis will showcase preclinical data on ensovibep, a COVID-19 treatment. Presentations also include discussions on ensuring safety and efficacy for AML therapies. Further details can be accessed via their official website.